docetaxel and cisplatin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Head and Neck Neoplasms
Conditions
Head and Neck Neoplasms
Trial Timeline
Oct 1, 2004 → Mar 1, 2008
NCT ID
NCT00772681About docetaxel and cisplatin
docetaxel and cisplatin is a approved stage product being developed by Sanofi for Head and Neck Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00772681. Target conditions include Head and Neck Neoplasms.
What happened to similar drugs?
10 of 20 similar drugs in Head and Neck Neoplasms were approved
Approved (10) Terminated (0) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00271323 | Phase 2 | Terminated |
| NCT00772681 | Approved | Completed |
| NCT00772863 | Phase 2 | Completed |
Competing Products
20 competing products in Head and Neck Neoplasms